| Literature DB >> 30459440 |
Emma J Mah1,2, Austin E Y T Lefebvre3,2, Gabrielle E McGahey3,2, Albert F Yee1,3, Michelle A Digman4,5,6.
Abstract
Extracellular matrix (ECM) mechanical properties upregulate cancer invasion, cell contractility, and focal adhesion formation. Alteration in energy metabolism is a known characteristic of cancer cells (i.e., Warburg effect) and modulates cell invasion. There is little evidence to show if collagen density can alter cancer cell metabolism. We investigated changes in energy metabolism due to collagen density in five breast cell lines by measuring the fluorescence lifetime of NADH. We found that only triple-negative breast cancer cells, MDA-MB231 and MDA-MB468 cells, had an increased population of bound NADH, indicating an oxidative phosphorylation (OXPHOS) signature, as collagen density decreased. When inhibiting ROCK and cell contractility, MDA-MB231 cells on glass shifted from glycolysis (GLY) to OXPHOS, confirming the intricate relationship between mechanosensing and metabolism. MCF10A cells showed less significant changes in metabolism, shifting towards GLY as collagen density decreased. The MCF-7 and T-47D, less invasive breast cancer cells, compared to the MDA-MB231 and MDA-MB468 cells, showed no changes regardless of substrate. In addition, OXPHOS or GLY inhibitors in MDA-MB231 cells showed dramatic shifts from OXPHOS to GLY or vice versa. These results provide an important link between cellular metabolism, contractility, and collagen density in human breast cancer.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30459440 PMCID: PMC6244401 DOI: 10.1038/s41598-018-35381-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Quantification of collagen substrates. (a) Second harmonic generation images of 3.0 mg/mL (n = 9) and 1.2 mg/mL collagen substrates (n = 7); where n = total number of collagen samples measured. (b) Modulus of collagen substrates at 10% strain and 1 Hz. (c) Quantification of fiber size (ωo) and (d) density of collagen substrates. *p < 1e-3, **p < 1e-26, ***p < 1e-57.
Figure 2Metabolic indexes of MDA-MB231 (3.0 mg/mL: n = 71; 1.2 mg/mL: n = 53; Glass: n = 77; Glass (Y-27632): n = 33), MDA-MB468 (3.0 mg/mL: n = 20; 1.2 mg/mL: n = 20; Glass: n = 5; Glass (Y-27632): n = 5), MCF7 (3.0 mg/mL: n = 20; 1.2 mg/mL: n = 21; Glass: n = 20; Glass (Y-27632): n = 21), T-47D (3.0 mg/mL: n = 5; 1.2 mg/mL: n = 5; Glass: n = 5; Glass (Y-27632): n = 5), and MCF10A (3.0 mg/mL: n = 64; 1.2 mg/mL: n = 59; Glass: n = 63; Glass (Y-27632): n = 26) cells on various collagen densities. (a) An increased population of bound NADH to LDH (long lifetime NADH, cyan) is indicative of a more OXPHOS signature while an increased population of free NADH (short lifetime NADH, red) would indicate GLY. These two extremes create a linear “M-trajectory” where a mixed population of bound and free NADH, for example 75%, will lie between these two points. (b) Percent increase of bound NADH in MDA-MB231, MDA-MB468, MCF7, T-47D, and MCF10A cells relative to glass. (c) Colored images of FLIM of NADH and the average intensity of NADH within MDA-MB231, MDA-MB468, MCF7, T-47D, and MCF10A cells. n = total number of cells measured. *p < 0.05, **p < 0.01, and ***p < 0.001 by Student’s t-test. Scale bar: 5 µm. Error bars are based on standard deviation.
Figure 3Metabolic indexes of A375MM (3.0 mg/mL: n = 24; 1.2 mg/mL: n = 23; Glass: n = 24; Glass (Y-27632): n = 28) and U251MG (3.0 mg/mL: n = 28; 1.2 mg/mL: n = 30; Glass: n = 26; Glass (Y-27632): n = 22) cells on various collage densities. (a) FLIM and average intensity images of NADH within A375MM melanoma and U251MG glioma cell lines. (b) Quantification of the percent change of NADH within A375MM and U251MG cell lines on various substrates relative to those on glass. (c) Transmitted optical images of A375MM and MDA-MB231 cells on different substrates. n = total number of cells measured. *p < 0.05, by Student’s t-test. Scale bar: 5 µm. Error bars are based on standard deviation.
Figure 4MDA-MB231 and MCF10A metabolic indexes when treated with metabolic inhibitors. (a) MDA-MB231 and (b) MCF10A cells treated with rotenone and antimycin A (R&A) or 2-deoxyglucose and dichloroacetate (2DG&DCA) for OXPHOS or GLY inhibition, respectively. FLIM images show the shifts in metabolic indexes with respective intensity images below. (c) Quantification of the change of bound NADH in MDA-MB231 with R&A (Glass: n = 29; 3.0 mg/mL: n = 29; 1.2 mg/mL: n = 29) or 2DG&DCA (Glass: n = 29; 3.0 mg/mL: n = 19; 1.2 mg/mL: n = 21) relative to untreated cells. (d) Quantification of the change of bound NADH in MCF10A with R&A (Glass: n = 25; 3.0 mg/mL: n = 20; 1.2 mg/mL: n = 15) or 2DG&DCA (Glass: n = 21; 3.0 mg/mL: n = 24; 1.2 mg/mL: n = 22) relative to untreated cells. n = total number of cells measured.*p < 0.05, **p < 0.01, and ***p < 0.001 or less by Student’s t-test. Scale bar: 5 µm. Error bars are based on standard deviation.